Orifarm Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD. The portfolio includes approximately 130 over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland. This divestment agreement was first announced in April 2020. The divested portfolio includes OTC products and food supplements, plus select products within the Cardiovascular, Anti-inflammatory, Respiratory, and Endocrinology therapeutic areas, primarily sold in Denmark, Norway, Belgium, Poland, Finland, Sweden, the Baltics and Austria. The portfolio generated FY2020 net sales of approximately $240 million USD, driven by sales of cough/cold and vitamin OTC brands, along with prescription product

United statesExchange commissionTakeda pharmaceutical company limitedOrifarm groupTakeda pharmaceutical companyFiscal yearsPharmaceutical company limitedRare geneticPlasma derived therapiesAnnual reportஒன்றுபட்டது மாநிலங்களில்பரிமாற்றம் தரகுடாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவைடாகேடா மருந்து நிறுவனம்நிதி ஆண்டுகள்மருந்து நிறுவனம் வரையறுக்கப்பட்டவை